Please login to the form below

brain

This page shows the latest brain news and features for those working in and with pharma, biotech and healthcare.

AbbVie’s Parkinson’s disease therapy application rejected by FDA

Parkinson's disease is a progressive and chronic neurological disorder resulting from the loss of dopamine-producing brain cells, which primarily manifests with tremor, muscle rigidity, slowness of movement and difficulty

Latest news

Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test

The test works by detecting traces of the toxic protein beta amyloid, which builds up in the brains of Alzheimer's patients. ... The decision from the US Food and Drug Administration was based on phase 2 data showing that Leqembi reduced the accumulation
Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration

This was based on phase 2 data showing that Leqembi reduced the accumulation of amyloid beta plaque in the brain, a defining feature of Alzheimer’s disease. ... Affecting more than 6.5 million Americans, Alzheimer’s disease is an irreversible,
FDA grants priority review for traditional approval of Biogen and Eisai’s Alzheimer’s drug

This decision was based on phase 2 data showing that Leqembi reduced the accumulation of amyloid beta plaque in the brain, a defining feature of Alzheimer’s disease. ... that the use of antithrombotic or thrombolytic medications while taking Aduhelm
Eli Lilly signs agreement worth up to $600m for Confo Therapeutics' non-opioid pain candidate

Currently in phase 1 clinical development, CFTX-1554 represents a non-opioid approach to treating neuropathic pain, a condition caused by damage to the nerves outside the brain and spinal cord.
Sanofi reports positive new data for multiple sclerosis treatment tolebrutinib

MS is a disabling, unpredictable neurological disease in which the immune system attacks the protective myelin sheath that covers the nerves and disrupts communication between the brain and the rest of ... Tim Turner, global project head for tolebrutinib

More from news
Approximately 10 fully matching, plus 732 partially matching documents found.

Latest Intelligence

Rare diseases: not so rare after all

As current enzyme replacement is typically administered by IV, and given that the drug is a protein, it will not cross the blood-brain barrier.
A relentless commitment to neuroscience

Technologies that facilitate and enhance transfer of biologics across the blood-brain barrier are also progressing at an exciting pace. ... For example, we’re exploring the potential for biospecific antibodies to help deliver therapeutic payloads
Mental health post-COVID-19: what are the consequences and lessons learned for healthcare?

Debilitating ‘long COVID’, estimated to affect at least 65 million people worldwide, is associated with neuropsychiatric sequelae such as fatigue, brain fog, memory loss, anxiety and depressive symptoms, and likely contributes
Preparing for a new era in Alzheimer’s disease

The disease takes many years to develop – alterations in the brain that cause AD can begin up to 20 years before the first symptoms are experienced.
Alzheimer’s Research UK highlights socio-economic inequalities in dementia risk

One large-scale study by the University of Luxembourg, which contributed to the findings, examined data taken from 196, 368 participants’ records, including brain scans, from the UK Biobank. ... Analysing the data from brain scans, the researchers also

More from intelligence
Approximately 0 fully matching, plus 70 partially matching documents found.

Latest appointments

Asceneuron appoints chief medical officer

His outstanding track record and expertise in neurodegenerative disease are crucial as we are about to progress our first highly brain penetrant and orally bioavailable tau modifier into the clinic for
Polleo Pharma co-founders join Chronos Therapeutics

In particular, their experience as co-founders of Polleo will be invaluable as we advance our behavioural brain disease portfolio.”.
Dr Niall Murphy and Pierre Schwich join Pharnext

He is currently an adjunct full professor of UCLA's department of psychiatry and biobehavioural sciences and a member of the Brain Research Institute at the David Geffen School of Medicine ... at the RIKEN Brain Science Institute.
Ex-GSK CEO Jean-Pierre Garnier takes up role at Alzheon

The firm focuses on brain health, memory and ageing and its lead product is an oral amyloid aggregation inhibitor that targets Alzheimer's disease.
Ovid Therapeutics adds member to scientific advisory board

Ovid is a privately-held biopharmaceutical company focused on developing therapies for rare and orphan diseases of the brain.

More from appointments
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest from PMHub

Could femtech be the answer to the gender health gap?

For example, the mental symptoms such as brain fog can be extremely debilitating but are rarely talked about.
Metahumans – the future of empathetic education?

Jonathan Cole’s study ‘ Empathy needs a face’ shows how ‘Human appearance and emotional expressivity may heighten empathy by enhancing the brain's ability to simulate being in another person's
Article: How behavioural economics can help you build better brand communications

System one thinking is all about instant gut reactions – the mental shortcuts, biases, and heuristics hard-wired into the human brain to help us survive. ... By applying the algorithm to pre-launch campaigns, you can replicate the way the human brain,
nzyme

Our specialist practices help deliver innovation and expertise, to truly put customers at the heart of the approach, and all backed up by the advice and support of our independent
Why big pharma needs to be braver

Imagine challenging or attempting to change a belief that someone has held for years, their brain might instinctively try and disregard it.

More from PMHub
Approximately 8 fully matching, plus 95 partially matching documents found.

Subscribe to our email news alerts

Senior Medical Writer: Highly competitive salary

Technical Sales Representative: Highly competitive salary

Pharmacovigilance Manager: Highly competitive salary

Associate Director - Global Healthcare Consulting: Highly competitive salary

Early Access Program - Regulatory Affairs (EAP-RA): Highly competitive salary

Omnichannel Account Director: £55,000 - £65,000 yearly

Strategy Director - Healthcare Advertising: Highly competitive salary

Pharmacovigilance Project Lead: Highly competitive salary

PMHub

Add my company

Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Rare diseases: not so rare after all: The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape: Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA: It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...

Email:
Password:

Please login to the form below

brain

Subscribe to our email news alerts

Quick links